咽淋巴环非霍奇金淋巴瘤101例临床及预后分析  

An analysis of the clinical manifestation and prognosis of 101 cases with non-Hodgkin's lymphoma of Waldeyer's ring

作　　者：励菁菁[1] 胡钧培[1] 

机构地区：[1]上海交通大学附属第九人民医院血液科,上海200011

出　　处：《临床血液学杂志》2007年第2期78-80,共3页Journal of Clinical Hematology

摘　　要：目的:分析多种因素对咽淋巴环非霍奇金淋巴瘤(NHL)预后的影响。方法:回顾性分析101例咽淋巴环NHL患者的临床资料。结果:根据Ann Arbor分期I a期占35．6％,I b期占8．9％,Ⅱa期占29．7％,Ⅱb期占6．9％,Ⅲa期占10．9％,Ⅲb期占5．0％,Ⅳa期占3．0％;B细胞来源NHL发病率为69．3％,T细胞来源NHL发病率为30．7％。全组病例1、3、5年年生存率分别为88．1％、75．3％、70．3％;B细胞来源为85．9％、74．7％、71．8％,T细胞来源分别为93．3％、76．7％、66．7％;I、Ⅱ、Ⅲ和Ⅳ期的5年生存率分别为84％、70％、44％和0％。临床资料单因素分析显示,年龄、一般状况评分、分期、B症状、肿瘤数目、首次治疗疗效、肿瘤大小、LDH、国际淋巴瘤预后指数(IPD均为咽淋巴环淋巴瘤生存期的预后相关因素(均P<0．05或P<0．01)。多因素分析提示,IPI、首次治疗疗效是咽淋巴环淋巴瘤生存期的独立预后因素。结论:IPI、首次治疗疗效是重要的预后因素,咽淋巴环NHL应采用综合治疗。Objective： To evaluate the factors on the prognosis of non-Hodgkin＇s lymphoma of Waldeyer＇s ring. Method： 101 patients with non-Hodgkin＇s lymphoma of Walderey＇s ring were reviewed retrospectively. Kaplan-Meier method was used in survival analysis, Logrank method in comparison and Cox regression model was used in determinating prognostic factors. Result：According to the Ann Arbor staging system, 35.6 % patients had stage Ⅰ a, 8.9% stage Ⅰ b, 29.7% stage Ⅱa, 6.9% stage Ⅱb, 10.9% stage Ⅲa, 5.0% stage Ⅲb and 3.0% stage Ⅳa. The incidence of B cell type was 69.3%, T cell type was 30. 7%. The group＇s 1,3.5 years survival rates were 88.1% .75.3% .70. 3%; B cell NHL were 85.9% .74.7% ,71.8%,T cell NHL were 93.3% .76.7% .66.7%. 5 years survival rate： stage Ⅰ、Ⅱ、Ⅲ and Ⅳ were 84%.70%,44% and 0%. In univariate analysis, age, performance status, B symptom, tumour number, first treatment response, tumour size, LDH level and International Prognostic Index （IPI） were prognostic related factors in the lymphoma of Walderey＇s ring （ P 〈0. 05）. In multivariate analysis, IPI and first treatment response were independent prognostic factors in the lymphoma of Walderey ＇s ring. Conclusion： IPI and first treatment response are important prognostic factors. The patients with non- Hodgkin＇s lymphoma of Waldeyer＇s ring should accept combined modality therapy.

关 键 词：淋巴瘤 非霍奇金 咽淋巴环 预后 综合疗法 

分 类 号：R733.4[医药卫生—肿瘤]